These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1353239)

  • 21. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Attempt at evaluation of alfacalcidol administered by an oral pulsatile method to chronically dialysed patients with advanced secondary hyperparathyroidism].
    Bunio A; Kwieciński R
    Wiad Lek; 1994 May; 47(9-10):342-5. PubMed ID: 7817591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).
    Molnár I; Stark N; Lovato J; Powell BL; Cruz J; Hurd DD; Mathieu JS; Chen TC; Holick MF; Cambra S; McQuellon RP; Schwartz GG
    Leukemia; 2007 May; 21(5):1089-92. PubMed ID: 17344922
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
    Takeda S; Kaneoka H; Saito T
    Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater efficacy of alfacalcidol in the red than in the yellow marrow skeletal sites in adult female rats.
    Tian XY; Liu XQ; Chen HY; Setterberg RB; Li M; Jee WS
    J Musculoskelet Neuronal Interact; 2008; 8(3):257-66. PubMed ID: 18799859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.
    Nakayamada S; Okada Y; Saito K; Tanaka Y
    J Rheumatol; 2004 Jan; 31(1):163-6. PubMed ID: 14705236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Low-dose melphalan therapy for patients with intermediate- to high-risk myelodysplastic syndromes].
    Liu L; Qin TJ; Xu ZF; Zhou CL; Zhang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):443-5. PubMed ID: 19954594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.
    Hoes JN; Jacobs JW; Hulsmans HM; De Nijs RN; Lems WF; Bruyn GA; Geusens PP; Bijlsma JW
    Clin Exp Rheumatol; 2010; 28(3):354-9. PubMed ID: 20406615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alfacalcidol in the therapy of renal bone disease.
    Ritzerfeld M; Klasser M; Mann H
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):546-50. PubMed ID: 11770836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
    Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
    Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes.
    Laporte JP; Isnard F; Fenaux P; Woler M; Najman A
    Contrib Nephrol; 1991; 88():271-2; discussion 273-5. PubMed ID: 2040189
    [No Abstract]   [Full Text] [Related]  

  • 33. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population.
    Shoji T; Shinohara K; Kimoto E; Emoto M; Tahara H; Koyama H; Inaba M; Fukumoto S; Ishimura E; Miki T; Tabata T; Nishizawa Y
    Nephrol Dial Transplant; 2004 Jan; 19(1):179-84. PubMed ID: 14671054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.
    Al-Hilali N; Al-Humoud H; Al-Helal B; Al-Azmi M; Al-Kandari NH; Johny KV
    Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
    Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
    Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
    Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of low-dose cytarabine therapy in myelodysplastic syndromes.
    el Mangoush M; Singh MK; Kumar S; Korajkio M; Gamati A
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():100. PubMed ID: 2627594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
    Kurzrock R; Estey E; Talpaz M
    J Clin Oncol; 1993 Aug; 11(8):1489-95. PubMed ID: 8336187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of myelodysplastic syndromes.
    Chng WJ
    N Engl J Med; 2005 May; 352(20):2134-5; author reply 2134-5. PubMed ID: 15901871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.